2024 ICD-10-CM Diagnosis Code T37.3X5D

Adverse effect of other antiprotozoal drugs, subsequent encounter

ICD-10-CM Code:
T37.3X5D
ICD-10 Code for:
Adverse effect of other antiprotozoal drugs, subs encntr
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics
        (T37)

T37.3X5D is a billable diagnosis code used to specify a medical diagnosis of adverse effect of other antiprotozoal drugs, subsequent encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T37.3X5D is a subsequent encounter code, includes a 7th character and should be used after the patient has completed active treatment for a condition like adverse effect of other antiprotozoal drugs. According to ICD-10-CM Guidelines a "subsequent encounter" occurs when the patient is receiving routine care for the condition during the healing or recovery phase of treatment. Subsequent diagnosis codes are appropriate during the recovery phase, no matter how many times the patient has seen the provider for this condition. If the provider needs to adjust the patient's care plan due to a setback or other complication, the encounter becomes active again.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Adverse reaction to antimony and/or antimony compound
  • Adverse reaction to diamidine
  • Adverse reaction to dichloroacetamide
  • Adverse reaction to emetine
  • Antiprotozoal drug adverse reaction
  • Atovaquone adverse reaction
  • Diloxanide adverse reaction
  • Nimorazole adverse reaction
  • Nitroimidazole adverse reaction
  • Nitroimidazole adverse reaction
  • Pentamidine adverse reaction
  • Sodium stibogluconate adverse reaction
  • Tinidazole adverse reaction

Clinical Classification

Clinical Information

  • Emetine

    the principal alkaloid of ipecac, from the ground roots of uragoga (or cephaelis) ipecacuanha or u. acuminata, of the rubiaceae. it is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. emetine inhibits protein synthesis in eukaryotic cells but not prokaryotic cells.
  • Glaucarubin

    (1 beta,2 alpha,11 beta,12 alpha,15 beta(s))-11,20-epoxy-1,2,11,12-tetrahydroxy-15-(2-hydroxy-2-methyl-1-oxobutoxy)picras-3-en-16-one. a quassinoid (simaroubolide) from simaruba glauca, a tropical shrub. it has been used as an antiamebic agent and is found to be cytotoxic. it may be of use in cancer chemotherapy.
  • Melarsoprol

    arsenical used in trypanosomiases. it may cause fatal encephalopathy and other undesirable side effects.
  • Misonidazole

    a nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. it may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.
  • Nifurtimox

    a nitrofuran thiazine that has been used against trypanosomiasis.
  • Nimorazole

    an antitrichomonal agent which is effective either topically or orally and whose urinary metabolites are also trichomonicidal.
  • Ornidazole

    a nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. it is partially plasma-bound and also has radiation-sensitizing action.
  • Pentamidine

    antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in hiv-infected patients. it may cause diabetes mellitus, central nervous system damage, and other toxic effects.
  • Tinidazole

    a nitroimidazole alkylating agent that is used as an antitrichomonal agent against trichomonas vaginalis; entamoeba histolytica; and giardia lamblia infections. it also acts as an antibacterial agent for the treatment of bacterial vaginosis and anaerobic bacterial infections.

Coding Guidelines

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics (T37). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)

T37.3X5D is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T37.3X5D to ICD-9-CM

  • ICD-9-CM Code: V58.89 - Other specfied aftercare
    Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Table of Drugs and Chemicals

The parent code T37.3X5 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
AcetarsolT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
ActerolT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
AminitrozoleT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
Antiprotozoal drug NECT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
Antiprotozoal drug NEC
  »blood
T37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
Antiprotozoal drug NEC
  »local
T37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
Antitrichomonal drugT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
ArsthinolT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
AzanidazoleT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
BenznidazoleT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
BialamicolT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
CarbarsoneT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
ClefamideT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
DehydroemetineT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
DHET37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
DHE
  »45
T37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
DifetarsoneT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
DiloxanideT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
EmetineT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
EtofamideT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
FlagylT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
GlaucarubinT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
GlycobiarsolT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
HydroxystilbamidineT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
Melarsonyl potassiumT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
MelarsoprolT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
MisonidazoleT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
NifurtimoxT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
NimorazoleT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
NitrimidazineT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
OrnidazoleT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
OxophenarsineT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
PentamidineT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
PhanquinoneT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
PhanquoneT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
SecnidazoleT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
StibogluconateT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
Stilbamidine (isetionate)T37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
TeclozanT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
TenonitrozoleT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
TinidazoleT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
Trichomonacides NECT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6
TryparsamideT37.3X1T37.3X2T37.3X3T37.3X4T37.3X5T37.3X6

Patient Education


Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

What is a drug interaction?

A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:

  • Two drugs, such as aspirin and blood thinners
  • Drugs and food, such as statins and grapefruit
  • Drugs and supplements, such as gingko and blood thinners
  • Drugs and medical conditions, such as aspirin and peptic ulcers

Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.

What are side effects?

Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.

What are drug allergies?

Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.

How can I stay safe when taking medicines?

When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.